Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of OMS721 for Treatment of Atypical Hemolytic Uremic Syndrome in Adults and Adolescents
2017-002057-11Phase 3Completed
- Sponsor
- Omeros Corporation
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of narsoplimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Omeros Corporation. Primary endpoint: Platelet count change from baseline at week 26. Started Aug 2017; status: completed.
02
Drugs
narsoplimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2017-002057-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002057-11.